









Markets
/
Stocks
/
nasdaq-fbrx
/

Forte Biosciences Inc

FBRX



View Detailed Chart

28.200USD

-1.130-3.85%

Market hours （ET）Quotes delayed by 15 min

353.17MMarket Cap

LossP/E TTM



Forte Biosciences Inc

28.200

-1.130-3.85%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-3.85%

5 Days

+28.42%

1 Month

+53.14%

6 Months

+92.36%

Year to Date

+24.17%

1 Year

+45.81%

View Detailed Chart

TradingKey Stock Score of Forte Biosciences Inc

Currency: USD Updated: 2025-12-22

Key Insights

Forte Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 86/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 54.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Forte Biosciences Inc's Score

Industry at a Glance

Industry Ranking

86 / 404

Overall Ranking

198 / 4578

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

54.800

Target Price

+177.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Forte Biosciences Inc Highlights

StrengthsRisks

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -361.61, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 566.74K shares of this stock.